Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the radiation therapy oncology group trials

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2740-2746

  Valicenti, Richard ^a   Lu, Jiandong ^a   Pilepich, Miljenko ^a   Asbell, Sucha ^a   Grignon, David ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0033911948     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2740     Document Type: Article

References (22)

1. Perez CA, Walz BJ, Zivnuska FR, et al: Irradiation of carcinoma of the prostate localized to the pelvis: Analysis of tumor response and prognosis. Int J Radiat Oncol Biol Phys 6:555-563, 1980
2. Hanks GE, Martz KL, Diamond JJ: The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15:1299-1305, 1988
3. Hanks G, Hanlon A, Sehultheiss T, et al: Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501-510, 1998
4. Stock RG, Stone NN, Tabert A, et al: A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101-108, 1998
5. Pollack A, Zagars G: External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39:1101-1018, 1997
6. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491-500, 1998
7. Roach M, Meehan S, Kroll S, et al: Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol 156:1719-1723, 1996
8. Hanks GE, Hanlon AL, Pinover WH, et al: Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 5:152-158, 1999
9. Asbell SO, Krall JM, Pilepich MV, et al: Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15:1307-1316, 1988
10. Pilepich MV, Krall JM Sause WT, et al: Prognostic factors in carcinoma of the prostate: Analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 13:339-349, 1987
11. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995
12. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
13. Roach M, Lu J, Pilepich M, et al: Long-term survival after radiotherapy alone: Radiation therapy oncology group prostate cancer trials. J Urol 161:864-868, 1999
14. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. International Commission on Radiation Units and Measurements: ICRU Report No. 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Washington. DC, International Commission on Radiation Units and Measurements, 1993
17. Landis SH, Murray T, Bolden S, et al: Cancer Statistics, 1999. CA Cancer J Clin 49:8-31, 1999
18. Chodak GW, Trusted RA, Gerber GS, et al: Results of conservation management of clinically localized prostate cancer. N Engl J Med 330:242-248, 1994
19. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years to diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980, 1998
20. Aus G. Hugosson J, Norlen L: Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154:460-465, 1995
21. Shipley WU, Verhey LJ, Munzenrider JE, et al: Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32:3-12, 1995
22. Lee WR, Hanks GE, Hanlon: An increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15:230-238, 1996